2022-06-16| Funding

Quion Licenses Two Rare Skin Disease Candidates to Hong Kong WinHealth

by Joy Lin
Share To

Quion is licensing two rare disease candidates to Hong Kong WinHealth Pharma Group, which could help the Virginia-based pharma break into the Greater China market. 

The partnership concerns Quion’s lead candidate QRX003, a topical lotion for Netherton Syndrome, a disorder characterized by abnormal skin shedding and a compromised skin barrier caused by the lack of the LEKTI protein, and QRX004 for Epidermolysis Bullosa, a group of rare inherited skin disorders that lead to fragile skin. 

QRX003 received IND clearance from the US FDA in April, and is expected to enter clinical testing this quarter. The drug contains a broad-spectrum serine protease inhibitor designed to perform the function LEKTI. According to Quion, daily application of QRX003 will lead to more normalized shedding of the skin and the formation of a stronger and more effective skin barrier.

Related article: Elektrofi Secures $40 Million in Series B Funding For Drug Delivery Development 


Choosing Partners For Asia and Europe


WinHealth will obtain rights to distribute the two products in the Greater China region, including Hong Kong, Macau, and Taiwan. With the latest agreement, Quion has established licensing partnerships for QRX003 in nearly 60 countries. 

WinHealth has extensive experience in bringing rare disease products to the China and Southeast Asia markets, explained Quion CEO Dr. Michael Myers. 

Their roster of global partnerships is a testament to their commitment to serving the rare disease community and Quoin is excited at becoming the latest addition to this stellar list, he added.

Companies that have partnered with WinHealth include Taiwan’s TWi Biotech, for an epidermolysis bullosa candidate, and Immedica Pharma, for Ravicti, a drug indicated for urea cycle disorders. 

Beyond Asia, Quion has partnered with ER-Kim to distribute QRX003 in 21 Central and Eastern European countries. For Russia, Quion has chosen Orpharm to distribute QRX003.

© All rights reserved. Collaborate with us:
Related Post
Reata’s Groundbreaking Therapy for an Ultra-rare Neuromuscular Disease Secures FDA Approval
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
Comparing ESG Regulations in the U.S., the U.K., and the EU
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
First-Ever Insect Brain Neuron Map Completed
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Scroll to Top